Physician profile
Lillian Soohoo
NPI 1629140819
$11,304.14
in general payments reported to CMS, 2019-2025
36 companies · $2,336 in 2025
The $2,336 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $894 · 2020: $506 · 2021: $364 · 2022: $843 · 2023: $2,898 · 2024: $3,464 · 2025: $2,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,263 · Education: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,263.12 |
| Education | $434.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,259.45 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Regeneron Healthcare Solutions, INC. | $1,640.96 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,055.51 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $799.26 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Janssen Biotech, INC. | $531.41 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Galderma Laboratories, L.P. | $474.14 | 2020-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $460.68 | 2020-2025 | |
| Revance Therapeutics, INC. | $436.84 | 2024-2025 | Daxxify, Daxi |
| Dermavant Sciences, INC. | $374.11 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $344.49 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $338.54 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $297.60 | 2022-2025 | Sotyktu |
| Almirall LLC | $270.40 | 2023-2025 | Klisyri |
| Incyte Corporation | $253.08 | 2022-2025 | Opzelura |
| Merz North America, INC. | $221.91 | 2022-2023 | Xeomin |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $201.82 | 2022-2023 | Percept PC Brainsense |
| Ucb, INC. | $171.17 | 2019 | |
| Leo Pharma INC. | $139.83 | 2019-2025 | Adbry |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $124.60 | 2019 | |
| Genentech USA, INC. | $119.74 | 2019 | |
| Horizon Therapeutics Plc | $117.21 | 2022 | |
| Pfizer INC. | $113.08 | 2024 | |
| Janssen Scientific Affairs, LLC | $71.01 | 2020 | |
| Allergan, INC. | $68.56 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $62.94 | 2023 | Idacio |
| Mayne Pharma Commercial LLC | $40.49 | 2020 | |
| Organon LLC | $39.74 | 2025 | Vtama |
| Amgen INC. | $31.03 | 2023 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.98 | 2023 | Spevigo |
| Botanix Sb INC | $21.00 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.74 | 2023 | Jublia, Duobrii, Arazlo |
| Solta Medical, A Division of Bausch Health US, LLC | $16.86 | 2022 | |
| Biofrontera INC. | $16.84 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Merck Sharp & Dohme LLC | $14.12 | 2019 | |
| Sensus Healthcare, INC. | $3.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lillian Soohoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.